Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
449 Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.